Introduction
Citicoline (CDP-Choline) is one of the most widely studied ingredients in nutraceutical formulations dedicated to cognitive and neurological wellness. As a physiological precursor of phosphatidylcholine, it plays a fundamental role in neuronal membrane synthesis and brain metabolism.
Its use is well established in formulations targeting cognitive function, memory, concentration, healthy aging, and neurological wellness, making it a benchmark ingredient in the brain-health nutraceutical market.
As formulation requirements continue to evolve, technologies capable of optimizing active-ingredient performance and formulation management have become increasingly important.
To address these needs, IPS has developed Citicoline MINIACTIVES®, a solution based on proprietary MINIACTIVES® technology, designed to provide controlled release and improved active-ingredient management within nutraceutical formulations.
Properties and application fields of Citicoline
Citicoline is widely used in several nutraceutical applications:
• Cognitive support
Widely used in formulations dedicated to memory, attention, and concentration.
• Neuronal metabolism
A precursor of essential structural components of cellular membranes.
• Healthy aging
Included in nutritional programs aimed at maintaining cognitive function over time.
• Neurological wellness
Used in formulations supporting nervous-system health.
Formulation challenges of Citicoline
Despite its high nutraceutical value, Citicoline presents several formulation challenges:
• Need for uniform active-ingredient distribution
• Requirement for controlled release according to formulation objectives
• Optimization of active management in complex formulations
• Demand for increasingly versatile dosage forms
These aspects highlight the importance of a dedicated technology capable of improving overall formulation quality.
IPS innovation: Citicoline MINIACTIVES®
Citicoline MINIACTIVES® is produced using proprietary MINIACTIVES® technology, a microencapsulation system developed to optimize active-ingredient performance.
Key technological benefits include:
• Controlled release of the active ingredient
• Improved distribution uniformity within formulations
• High formulation flexibility
• Greater versatility across dosage forms
• Improved technological management during manufacturing
The system is designed to modulate release without altering the nature of Citicoline.
Scientific evidence
Citicoline is one of the two ingredients for which direct clinical studies on MINIACTIVES® technology are available.
Clinical evidence demonstrated:
• improved release profile
• increased bioaccessibility
• improved tolerability
• optimized active availability over time
These findings confirm the determining role of MINIACTIVES® technology in the behavior of microencapsulated Citicoline and provide direct validation of the technological platform.
Formulations and applications
Citicoline MINIACTIVES® is suitable for:
• capsules
• tablets
• sachets and stick packs
• dosing-cap vials
• SmarTTabs®, technological innovation by IPS for direct compression, preserving MINIACTIVES® characteristics
This versatility enables the development of highly flexible formulations dedicated to cognitive and neurological wellness.
Conclusion
Citicoline is one of the most important ingredients in cognitive and neurological nutraceuticals.
With Citicoline MINIACTIVES®, IPS provides an advanced technological solution combining controlled release, formulation flexibility, and direct clinical validation, enabling formulators to develop innovative, high-performance products.
The MINIACTIVES® technology further confirms the role of the SURACTIVES® division of IPS as a technology provider in the development of innovative and scientifically supported nutraceutical ingredients.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
